CA3183242A1 - Compositions et procedes de modulation de la transduction du signal mediee par flrt3 - Google Patents
Compositions et procedes de modulation de la transduction du signal mediee par flrt3Info
- Publication number
- CA3183242A1 CA3183242A1 CA3183242A CA3183242A CA3183242A1 CA 3183242 A1 CA3183242 A1 CA 3183242A1 CA 3183242 A CA3183242 A CA 3183242A CA 3183242 A CA3183242 A CA 3183242A CA 3183242 A1 CA3183242 A1 CA 3183242A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- flrt3
- antibody
- variable region
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Steroid Compounds (AREA)
Abstract
L'invention concerne des compositions et leurs procédés d'utilisation pour moduler la signalisation médiée par FLRT3. Par exemple, l'invention concerne des agents immunomodulateurs qui réduisent l'expression de FLRT3, la liaison de ligands, la réticulation, la signalisation médiée par FLRT3, ou une combinaison de celles-ci. Dans un autre mode de réalisation, l'invention concerne des agents immunomodulateurs qui améliorent ou favorisent l'expression de FLRT3, la liaison de ligands, la réticulation, la signalisation médiée par FLRT3, ou une combinaison de celles-ci. Ces agents peuvent être utilisés pour moduler la réponse immunitaire chez un sujet en ayant besoin.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063040654P | 2020-06-18 | 2020-06-18 | |
US63/040,654 | 2020-06-18 | ||
PCT/US2021/038201 WO2021258040A2 (fr) | 2020-06-18 | 2021-06-21 | Compositions et procédés de modulation de la transduction du signal médiée par flrt3 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3183242A1 true CA3183242A1 (fr) | 2021-12-23 |
Family
ID=79268748
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3183242A Pending CA3183242A1 (fr) | 2020-06-18 | 2021-06-21 | Compositions et procedes de modulation de la transduction du signal mediee par flrt3 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2023530489A (fr) |
CN (1) | CN116322748A (fr) |
AU (1) | AU2021293287A1 (fr) |
CA (1) | CA3183242A1 (fr) |
WO (1) | WO2021258040A2 (fr) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
JP6590284B2 (ja) * | 2015-02-13 | 2019-10-16 | 国立大学法人大阪大学 | 疼痛抑制物質のスクリーニング方法および疼痛の予防または治療用医薬組成物 |
WO2017083515A2 (fr) * | 2015-11-10 | 2017-05-18 | Visterra, Inc. | Conjugués molécules anticorps-médicaments et leurs utilisations |
US10617773B2 (en) * | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
-
2021
- 2021-06-21 JP JP2022578562A patent/JP2023530489A/ja active Pending
- 2021-06-21 AU AU2021293287A patent/AU2021293287A1/en active Pending
- 2021-06-21 WO PCT/US2021/038201 patent/WO2021258040A2/fr unknown
- 2021-06-21 CA CA3183242A patent/CA3183242A1/fr active Pending
- 2021-06-21 CN CN202180050412.4A patent/CN116322748A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023530489A (ja) | 2023-07-18 |
AU2021293287A1 (en) | 2023-02-16 |
WO2021258040A2 (fr) | 2021-12-23 |
WO2021258040A3 (fr) | 2022-01-27 |
CN116322748A (zh) | 2023-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11390675B2 (en) | Antibodies for Siglec-15 and methods of use thereof | |
RU2757394C2 (ru) | Композиции и способы для модуляции передачи сигнала lair | |
US20240076379A1 (en) | Antibodies to programmed cell death protein 1 | |
JP2019536470A6 (ja) | シグレック−15に対する抗体及びその使用方法 | |
CA3089469A1 (fr) | Anticorps anti-b7-h4 et leurs procedes d'utilisation | |
US20210002373A1 (en) | KLRG1 Binding Compositions and Methods of Use Thereof | |
US20230357384A1 (en) | Compositions and methods for modulating flrt3 mediated signal transduction | |
CA3183242A1 (fr) | Compositions et procedes de modulation de la transduction du signal mediee par flrt3 | |
RU2809243C2 (ru) | Антитела в7-н4 и способы их применения | |
RU2812915C2 (ru) | Антитела к белку программируемой клеточной смерти 1 | |
EP4360714A2 (fr) | Anticorps pour siglec-15 et leurs procédés d'utilisation |